MDxHealth is a molecular diagnostics company that develops and commercializes advanced tests for cancer assessment and the personalized treatment of patients. Applying our patented DNA methylation platform and biomarkers, we help address a large and growing unmet medical need for better cancer diagnosis and treatment information. MDxHealth is a publicly-listed company trading on the NYSE Euronext (NYSE as in New York Stock Exchange) markets of Brussels and Amsterdam under the ticker symbol "MDXH". MDxHealth (formerly OncoMethylome Sciences) was established in 2003 and is headquartered in Belgium. Its US headquarters is located in Durham, NC. MDxHealth develops molecular diagnostic products on its own or in partnership with pharmaceutical companies. Some of its products are already commercialized and the company has a broad pipeline of other products for major cancer indications.
Type
Public
HQ
Herstal, BE
Founded
2004
Size (employees)
162 (est)+22%
MDxHealth was founded in 2004 and is headquartered in Herstal, BE
Report incorrect company information

Key People/Management at MDxHealth

Jan Groen

Jan Groen

President and Chief Executive Officer
Joseph Sollee

Joseph Sollee

Executive Vice President of Corporate Development and General Counsel
Jean-Marc Roelandt

Jean-Marc Roelandt

CFO
Michael Brawer

Michael Brawer

Chief Medical Officer

MDxHealth Office Locations

MDxHealth has offices in Herstal, Irvine and Nijmegen
Herstal, BE (HQ)
31 Rue d'Abhooz
Nijmegen, NL
34 Geert Grooteplein Zuid
Irvine, US
100 15279 Alton Pkwy
Show all (3)
Report incorrect company information

MDxHealth Financials and Metrics

MDxHealth Financials

Market capitalization (10-Nov-2016)

237.9 b

Closing share price (10-Nov-2016)

4.6
MDxHealth's current market capitalization is €237.9 b.
Show all financial metrics
Report incorrect company information

MDxHealth Online and Social Media Presence

Embed Graph
Report incorrect company information